Pharmaceutical - Johnson & Johnson

Filter

Current filters:

Johnson & Johnson

Popular Filters

201 to 225 of 257 results

Disappointing FDA views for Bayer's Xarelto and Pozen ulcer drug

22-06-2012

Bayer HealthCare, a unit of Germany's Bayer (BAYN: DE) says that it has received a complete response…

BayerCardio-vascularGastro-intestinalsJohnson & JohnsonNorth AmericaPA32540PharmaceuticalPozenRegulationXarelto

Johnson & Johnson units file for new Zytiga use in USA and EU

18-06-2012

Janssen Research & Development, a subsidiary of US drugs giant Johnson & Johnson (NYSE: JNJ), has submitted…

EuropeJanssenJohnson & JohnsonNorth AmericaOncologyPharmaceuticalRegulationZytiga

Five more drug majors join NIH initiative to speed therapeutic discovery

13-06-2012

Five additional pharmaceutical companies have joined a US National Institutes of Health-led effort to…

Abbott LaboratoriesBristol-Myers SquibbGlaxoSmithKlineJohnson & JohnsonNorth AmericaPharmaceuticalResearchSanofi

Alkermes and J&J initiate Ph III trial of three-month Invega Sustenna

12-06-2012

USA-based Alkermes (Nasdaq: ALKS) and partner health care giant Johnson & Johnson (NYSE: JNJ) have started…

AlkermesInvega SustennaJohnson & JohnsonNeurologicalPharmaceuticalResearch

US regulator puts conditions on Johnson & Johnson's proposed buy of Synthes

12-06-2012

The US Federal Trade Commission will require health care giant Johnson & Johnson (NYSE: JNJ) to sell…

Johnson & JohnsonMergers & AcquisitionsNorth AmericaPharmaceuticalRegulationSynthes

ASCO 2012: "Show me the overall survival data," say analysts

07-06-2012

The annual American Society of Clinical Oncology (ASCO) meeting, held this year in Chicago from June…

GenentechJohnson & JohnsonOncologyPharmaceuticalResearchRochetrastuzumab emtansineZytiga

More news at EULAR from Novartis, J&S and B-MS

07-06-2012

Highlights presented at the annual congress of the European League Against Rheumatism (EULAR 2012), in…

Anti-Arthritics/RheumaticsBristol-Myers SquibbIlarisJohnson & JohnsonNovartisOrenciaPharmaceuticalResearchSimponi InjectionStelara Injection

Flood of new cancer drug data presented at ASCO; nearly 1,000 being tested

04-06-2012

The annual prestigious American Society of Clinical Oncology (ASCO) meeting taking place in Chicago,…

afatinibBiotechnologyBoehringer IngelheimGenentechJanssenJohnson & JohnsonOncologyPharmaceuticalResearchRochetrastuzumab emtansineZytiga

Janssen files NDA with FDA for canagliflozin in type 2 diabetes

01-06-2012

Janssen Research & Development, a subsidiary of health care giant Johnson & Johnson (NYSE: JNJ) has submitted…

canagliflozinDermatologicalsJanssenJohnson & JohnsonMitsubishi TanabeNorth AmericaPharmaceuticalRegulation

US FDA advisory panel votes against added indication for Bayer's Xarelto

24-05-2012

Despite relatively positive briefing papers earlier this week (The Pharma Letter May 22), the US Food…

BayerCardio-vascularJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

FDA staffers basically back Xarelto for ACS but identify missing data in study

22-05-2012

The US Food and Drug Administration advisory panelists due to revue Johnson & Johnson (NYSE: JNJ) and…

BayerCardio-vascularJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

Positive Ph III results for J&J's Nucynta in diabetic peripheral neuropathy

18-05-2012

Janssen Pharmaceuticals, a unit of health care major Johnson & Johnson yesterday announced the results…

DiabetesJanssenJohnson & JohnsonNeurologicalNucyntaPharmaceuticalResearch

UK's NICE does U-turn, recommending Zytiga as Janssen cuts price

16-05-2012

UK drugs watch dog the National Institute for Health and Clinical Excellence (NICE) has reversed an earlier…

EuropeJanssenJohnson & JohnsonOncologyPharmaceuticalPricingRegulationZytiga

Furiex Pharma gets rights to Priligy, some of which it sells on to Menarini

15-05-2012

In a two part transaction, USA-based Furiex Pharmaceuticals (Nasdaq: FURX) has entered into an agreement…

ALZA CorpFuriex PharmaceuticalsJanssen PharmaceuticaJohnson & JohnsonLicensingMen's HealthMenariniPharmaceuticalPriligy

UK academia-pharma collaboration attracts £14.4 million funding

13-05-2012

In the UK, the University of Dundee and the Medical Research Council (MRC) have announced new funding…

AstraZenecaBoehringer IngelheimEuropeFinancialGlaxoSmithKlineJohnson & JohnsonMerck SeronoPfizerPharmaceuticalResearch

EU Commission OKs J&J's buy of Synthes, but with conditions

22-04-2012

The European Commission last week cleared under the EU Merger Regulation the proposed $21.3 billion acquisition…

Johnson & JohnsonMergers & AcquisitionsPharmaceuticalSynthes

Bristol-Myers expands hepatitis C accord with Medivir and Janssen

18-04-2012

Swedish infectious disease drug developer Medivir AB (OMX: MVIR) said yesterday that its development…

Anti-viralsBristol-Myers SquibbdaclatasvirJanssenJohnson & JohnsonLicensingMedivirPharmaceuticalResearch

Johnson & Johnson 1st-qtr earnings up 12.5% but sales flat

18-04-2012

US health care giant Johnson & Johnson (NYSE: JNJ) posted first-quarter 2012 financial results in line…

FinancialJohnson & JohnsonPharmaceutical

News briefs on Janssen, Bayer and Merck KGaA/Threshold

12-04-2012

In the USA, the Arkansas jury found that the Janssen unit of US health care giant Johnson & Johnson (NYSE:…

BayerFinancialJanssenJohnson & JohnsonLegalMerck KGaAPharmaceuticalRegulationRisperdalThreshold PharmaceuticalsXarelto

201 to 225 of 257 results

Parexel

Parexel

Back to top